X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (326) 326
Publication (53) 53
Conference Proceeding (32) 32
Book Review (26) 26
Patent (12) 12
Book / eBook (6) 6
Book Chapter (4) 4
Paper (4) 4
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (144) 144
humans (124) 124
oncology (116) 116
male (94) 94
female (88) 88
middle aged (79) 79
aged (76) 76
adult (50) 50
colorectal cancer (47) 47
chemotherapy (42) 42
colorectal neoplasms - drug therapy (40) 40
colorectal neoplasms - pathology (40) 40
treatment outcome (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
metastasis (35) 35
analysis (32) 32
astronomy & astrophysics (32) 32
aged, 80 and over (31) 31
care and treatment (30) 30
camptothecin - analogs & derivatives (29) 29
cancer (29) 29
fluorouracil - administration & dosage (29) 29
camptothecin - administration & dosage (25) 25
disease-free survival (25) 25
bevacizumab (23) 23
leucovorin - administration & dosage (23) 23
oxaliplatin (23) 23
prognosis (23) 23
research (23) 23
neoplasm metastasis (22) 22
physics - solar and stellar astrophysics (22) 22
retrospective studies (22) 22
stars: dwarf novae (22) 22
therapy (22) 22
5-fluorouracil (21) 21
tumors (21) 21
accretion, accretion disks (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
colorectal neoplasms - genetics (20) 20
survival (20) 20
cetuximab (19) 19
irinotecan (19) 19
1st-line treatment (18) 18
leucovorin (18) 18
liver neoplasms - drug therapy (18) 18
astrophysics (17) 17
stars: individual (17) 17
fluorouracil (16) 16
liver metastases (16) 16
medicine & public health (16) 16
metastatic colorectal cancer (16) 16
surgery (16) 16
organoplatinum compounds - administration & dosage (15) 15
accretion disks (14) 14
astrophysics - solar and stellar astrophysics (14) 14
drug therapy (14) 14
kaplan-meier estimate (14) 14
liver neoplasms - secondary (14) 14
metastases (14) 14
mutation (14) 14
physics - cosmology and nongalactic astrophysics (14) 14
cataclysmic variables (13) 13
chemistry (13) 13
clinical trials (13) 13
colorectal carcinoma (13) 13
radiotherapy (13) 13
trial (13) 13
adolescent (12) 12
colorectal neoplasms - mortality (12) 12
genetic aspects (12) 12
metallurgy (12) 12
panitumumab (12) 12
risk factors (12) 12
survival analysis (12) 12
antineoplastic agents - therapeutic use (11) 11
hematology, oncology and palliative medicine (11) 11
neoplasm staging (11) 11
pharmacology & pharmacy (11) 11
physics (11) 11
proto-oncogene proteins b-raf - genetics (11) 11
abridged index medicus (10) 10
adenocarcinoma - drug therapy (10) 10
braf (10) 10
capecitabine (10) 10
drug administration schedule (10) 10
infusions, intravenous (10) 10
italy (10) 10
kras (10) 10
patients (10) 10
stars: novae, cataclysmic variables (10) 10
superhumps (10) 10
usage (10) 10
accretion (9) 9
antibodies, monoclonal - administration & dosage (9) 9
antineoplastic agents (9) 9
cancer research (9) 9
clinical neurology (9) 9
disease (9) 9
expression (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852
Summary Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil,... 
Hematology, Oncology and Palliative Medicine | LIVER METASTASES | INFUSIONAL FLUOROURACIL | LEUCOVORIN | K-RAS | PLUS IRINOTECAN | ONCOLOGY | CLINICAL-TRIALS | TUMOR RESPONSE | ORAL FLUOROPYRIMIDINES | BICC-C | CHEMOTHERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Angiogenesis inhibitors | Drug therapy | Cancer | Medical research | Analysis | Medicine, Experimental | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2622 - 2629
Purpose PTEN, AKT, and KRAS are epidermal growth factor receptor (EGFR) downstream regulators. KRAS mutations confer resistance to cetuximab. This... 
CELL LUNG-CANCER | PANITUMUMAB | K-RAS MUTATIONS | THERAPY | GROWTH-FACTOR-RECEPTOR | EFFICACY | ONCOLOGY | SIGNALING PATHWAY | RESISTANCE | EGFR | CHEMOTHERAPY | Immunohistochemistry | Predictive Value of Tests | ras Proteins - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | PTEN Phosphohydrolase - analysis | Drug Resistance, Neoplasm | Male | Patient Selection | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Phytogenic - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Colorectal Neoplasms - enzymology | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins c-akt - analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Colorectal Neoplasms - secondary | Italy - epidemiology | Aged | Mutation | Longitudinal Studies | Index Medicus
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 11/2013, Volume 98, Issue 11, pp. 1732 - 1738
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 83 - 90
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in... 
metastatic colorectal cancer | NRAS | BRAF | KRAS | anti‐EGFR | anti-EGFR | 1ST-LINE TREATMENT | N-RAS | MICROSATELLITE INSTABILITY | KRAS WILD-TYPE | COLON-CANCER | PANITUMUMAB | K-RAS | ONCOLOGY | BRAF MUTATIONS | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Liver Neoplasms - mortality | DNA Mutational Analysis | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Liver Neoplasms - secondary | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Liver Neoplasms - genetics | Membrane Proteins - genetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Chemotherapy | Gene mutations | Analysis | Colorectal cancer | Monoclonal antibodies | Genetic aspects | Metastasis | Cancer | Mutation | Medical prognosis | Tumors | Index Medicus
Journal Article
by Jan Schipper and Janice S. Chanson and Federica Chiozza and Neil A. Cox and Michael Hoffmann and Vineet Katariya and John Lamoreux and Ana S. L. Rodrigues and Simon N. Stuart and Helen J. Temple and Jonathan Baillie and Luigi Boitani and Thomas E. Lacher and Russell A. Mittermeier and Andrew T. Smith and Daniel Absolon and John M. Aguiar and Giovanni Amori and Noura Bakkour and Ricardo Baldi and Richard J. Berridge and Jon Bielby and Patricia Ann Black and J. Julian Blanc and Thomas M. Brooks and James A. Burton and Thomas M. Butynski and Gianluca Catullo and Roselle Chapman and Zoe Cokeliss and Ben Collen and Jim Conroy and Justin G. Cooke and Gustavo A. B. da Fonseca and Andrew E. Derocher and Holly T. Dublin and J. W. Duckworth and Louise Emmons and Richard H. Emslie and Marco Festa-Bianchet and Matt Foster and Sabrina Foster and David L. Garshelis and Cormack Gates and Mariano Gimenez-Dixon and Susana Gonzalez and Jose Fernando Gonzalez-Maya and Tatjana C. Good and Geoffrey Hammerson and Philip S. Hammond and David Happold and Meredith Happold and John Hare and Richard B. Harris and Clare E. Hawkins and Mandy Haywood and Lawrence R. Heaney and Simon Hedges and Kristofer M. Helgen and Craig Hilton-Taylor and Syed Ainul Hussain and Nobuo Ishii and Thomas A. Jefferson and Richard K. B. Jenkins and Charlotte H. Johnston and Mark Keith and Jonathan Kingdon and David H. Knox and Kit M. Kovacs and Penny Langhammer and Kristin Leus and Rebecca Lewison and Gabriela Lichtenstein and Lloyd F. Lowry and Zoe Macavoy and Georgina M. Mace and David P. Mallon and Monica Masi and Meghan W. McKnight and Rodrigo A. Medellín and Patricia Medici and Gus Mills and Patricia D. Moehlman and Sanjay Molur and Arturo Mora and Kristin Nowell and John F. Oates and Wanda Olech and William R. L. Oliver and Monik Oprea and Bruce D. Patterson and William F. Perrin and Beth A. Polidoro and Caroline Pollock and Abigail Powel and Yelizaveta Protas and Paul Racey and Jim Ragle and Pavithra Ramani and Galen Rathbun and ...
Science, ISSN 0036-8075, 10/2008, Volume 322, Issue 5899, pp. 225 - 230
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2007, Volume 25, Issue 10, pp. 1247 - 1254
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 01/2011, Volume 103, Issue 1, pp. 21 - 30
Journal Article
BMC Cancer, ISSN 1471-2407, 08/2009, Volume 9, Issue 1, pp. 303 - 303
Journal Article